Volume 29, issue 8, August 2022

150 articles in this issue

1. One Step at a Time: Implementing Pathways to Optimize the Care of Geriatric Surgical Patients

2. Personal Systemic Therapy Decision-Making has Officially Arrived for Node-Positive Breast Cancer

3. The EA2108 Clinical Trial and Real-World Data: A Cautionary Tale in Stage IV Breast Cancer

4. A Woman Needs to Know She Is a BRCA Carrier Before She Develops Breast Cancer

5. Updates to the Literature on Anastomotic Leaks After Rectosigmoid Resection for Gynecologic Malignancies

6. Treatment of Oligometastatic Esophagogastric Cancer: A Spark of Light at the End of the Tunnel

7. An Editorial on Lymphadenectomy in Esophagectomy for Cancer

8. The Increasing Role of Surgery in Comprehensive Treatment of Advanced Non-small Cell Lung Cancer with Targetable Mutations

9. Association of the Modified Albumin–Bilirubin Grade with Survival Outcomes in Esophageal Squamous Cell Carcinoma

10. Invited Editorial: Comprehensive Analysis of Molecular Biological Characteristics of Pancreatic Ductal Adenocarcinoma Concomitant with Intraductal Papillary Mucinous Neoplasm

11. A Randomized, Phase III Study of Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) in High-Risk Patients with Stage I Non-Small Cell Lung Cancer (NSCLC)

12. Osimertinib, Surgery, and Radiation Therapy in Treating Patients with Stage IIIB or IV Non-Small Cell Lung Cancer with EGFR Mutations (NORTHSTAR)

13. The Association of Frailty with Outcomes after Cancer Surgery: A Systematic Review and Metaanalysis

14. ASO Visual Abstract: The Association of Frailty with Outcomes After Cancer Surgery—A Systematic Review and Meta-Analysis

15. Comparison of Outcomes Between BRCA Pathogenic Variant Carriers Undergoing Breast-Conserving Surgery Versus Mastectomy

16. ASO Visual Abstract: Comparison of Outcomes Between BRCA Pathogenic Variant Carriers Undergoing Breast-Conserving Surgery and Those Treated With Mastectomy

17. Epigenetic Signatures Predict Pathologic Nodal Stage in Breast Cancer Patients with Estrogen Receptor-Positive, Clinically Node-Positive Disease

18. ASO Author Reflections: Entering the Era of Biomarker-Driven Management of the Axilla

19. ASO Visual Abstract: Epigenetic Signatures Predict Pathologic Nodal Stage in Breast Cancer Patients with Estrogen-Receptor-Positive, Clinically Node-Positive Disease

20. Time to Surgical Treatment and Facility Characteristics as Potential Drivers of Racial Disparities in Breast Cancer Mortality

21. ASO Visual Abstract: Time to Surgical Treatment and Facility Characteristics as Potential Drivers of Racial Disparities in Breast Cancer Mortality: Delay, Facilities, and Breast Cancer Mortality

22. Contemporary Axillary Management in cT1–2N0 Breast Cancer with One or Two Positive Sentinel Lymph Nodes: Factors Associated with Completion Axillary Lymph Node Dissection Within the National Cancer Database

23. ASO Author Reflections: Axillary Management in Mastectomy Patients with Limited Nodal Burden

24. ASO Visual Abstract: Contemporary Axillary Management in cT1-2N0 Breast Cancer with 1–2 Positive Sentinel Lymph Nodes: Factors Associated with Completion Axillary Lymph Node Dissection Within the National Cancer Database

25. Impact of Endocrine Therapy Adherence on Outcomes in Elderly Women with Early-Stage Breast Cancer Undergoing Lumpectomy Without Radiotherapy

26. ASO Author Reflections: Undertreatment of Early-Stage Breast Cancer in Elderly Women Undergoing Lumpectomy Without Radiotherapy Increases the Risk of Locoregional Recurrence

27. ASO Visual Abstract: Impact of Endocrine Therapy Adherence on Outcomes in Elderly Women With Early-Stage Breast Cancer Undergoing Lumpectomy Without Radiotherapy

28. Preoperative Sonographic Prediction of Limited Axillary Disease in Patients with Primary Breast Cancer Meeting the Z0011 Criteria: an Alternative to Sentinel Node Biopsy?

29. ASO Author Reflections: An Alternative to Sentinel-Node Biopsy? Preoperative Sonographic Prediction of Limited Axillary Disease in Breast Cancer Patients Meeting the Z0011 Criteria

30. ASO Visual Abstract: Preoperative Sonographic Prediction of Limited Axillary Disease in Patients with Primary Breast Cancer Meeting the Z0011 Criteria: An Alternative to Sentinel-Node-Biopsy?

31. The Use of Pectoralis Blocks in Breast Surgery: A Practice Advisory and Narrative Review from the Society for Ambulatory Anesthesia (SAMBA)

32. ASO Author Reflections: SAMBA’s Practice Advisory for the Use of Pectoralis Blocks in Breast Surgery: Overview and Lingering Questions

33. ASO Visual Abstract: The Use of Pectoralis Blocks in Breast Surgery: A Practice Advisory and Narrative Review From the Society for Ambulatory Anesthesia (SAMBA)

34. Risk Factors for Anastomotic Leakage in Advanced Ovarian Cancer Surgery: A Large Single-Center Experience

35. ASO Author Reflections: Risk Factors for Anastomotic Leakage in Advanced Ovarian Cancer Surgery—What We Know and Future Perspectives

36. ASO Visual Abstract: Risk Factors for Anastomotic Leakage in Advanced Ovarian Cancer Surgery: A large Single-Center Experience

37. Clinical Impact of Pathologic Residual Tumor in Locally Advanced Cervical Cancer Patients Managed by Chemoradiotherapy Followed by Radical Surgery: A Large, Multicenter, Retrospective Study

38. ASO Author Reflections: Role of Adjuvant Surgery in Locally Advanced Cervical Cancer: An Unresolved Issue

39. ASO Visual Abstract: Clinical Impact of Pathological Residual Tumor in Locally Advanced Cervical Cancer Patients Managed by Chemoradiotherapy Followed by Radical Surgery: A Large, Multicenter, Retrospective Study

40. SUCCOR Risk: Design and Validation of a Recurrence Prediction Index for Early-Stage Cervical Cancer

41. ASO Author Reflections: Will Conization Become a Standard Maneuver Before Radical Hysterectomy?

42. ASO Visual Abstract: SUCCOR Risk—Design and Validation of a Recurrence Prediction Index for Early-Stage Cervical Cancer

43. Adjuvant Use of PlasmaJet Device During Cytoreductive Surgery for Advanced-Stage Ovarian Cancer: Results of the PlaComOv-study, a Randomized Controlled Trial in The Netherlands

44. ASO Author Reflections: The PlasmaJet® Device Contributes to an Increase in the Number of Complete Cytoreductive Surgeries for Ovarian Cancer Patients

45. ASO Visual Abstract: The Role of Adjuvant Use of the PlasmaJet® Device During Cytoreductive Surgery for Advanced-Stage Ovarian Cancer—Results of the PlaComOv-Study, a Randomized, Controlled Trial in the Netherlands

46. Metastasectomy or Stereotactic Body Radiation Therapy With or Without Systemic Therapy for Oligometastatic Esophagogastric Cancer

47. ASO Author Reflections: Role of Local Treatment for Oligometastatic Esophagogastric Cancer

48. ASO Visual Abstract: Metastasectomy or Stereotactic Body Radiation Therapy With or Without Systemic Therapy for Oligometastatic Esophagogastric Cancer

49. Selective Lymphadenectomy for Salvage Esophagectomy in Patients with Esophageal Squamous Cell Carcinoma

50. ASO Author Reflections: Safety and Curability of Lymphadenectomy for Salvage Esophagectomy

51. ASO Visual Abstract: Selective Lymphadenectomy for Salvage Esophagectomy in Patients with Esophageal Squamous Cell Carcinoma

52. Primary Tumor Resection for Stage IV Non-small-cell Lung Cancer Without Progression After First-Line Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Treatment: A Retrospective Case–Control Study

53. ASO Author Reflection: Primary Tumor Resection for Stage IV Lung Cancer after Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor

54. ASO Visual Abstract: Primary Tumor Resection for Stage IV Non-Small-Cell Lung Cancer Without Progression After First-Line Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Treatment: A Retrospective Case-Control Study

55. Prognostic Value of a Modified Albumin–Bilirubin Score Designed for Patients with Esophageal Squamous Cell Carcinoma After Radical Resection

56. ASO Author Reflections: Optimized Cutoff Value of Albumin–Bilirubin Score to Predict Prognosis of Patients with Esophageal Squamous Cell Carcinoma After Radical Resection

57. ASO Visual Abstract: Prognostic Value of a Modified Albumin–Bilirubin Grade Designed for Patients with Esophageal Squamous Cell Carcinoma after Radical Resection

58. Prognostic Impact of Number of Organ Invasions in Patients with Surgically Resected Thymoma

59. ASO Visual Abstract: Prognostic Impact of the Number of Organ Invasions in Patients with Surgically Resected Thymoma

60. Skeletonizing En Bloc Esophagectomy Revisited: Oncologic Outcome in Association with the Presence of Thoracic Duct Lymph Nodes

61. ASO Author Reflections: The Role of Skeletonizing en bloc Esophagectomy in Esophageal Squamous Cell Carcinoma

62. ASO Visual Abstract: Skeletonizing En Bloc Esophagectomy Revisited—Oncologic Outcome in Association with Presence of Thoracic Duct Lymph Nodes

63. Correction to: Primary Tumor Resection for Stage IV Non-small-cell Lung Cancer Without Progression After First-Line Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Treatment: A Retrospective Case–Control Study

64. Correction to: Establishment of Minimal Clinically Important Improvement for Patient-Reported Symptoms to Define Recovery After Video-Assisted Thoracoscopic Surgery

65. Comprehensive Analysis of Molecular Biologic Characteristics of Pancreatic Ductal Adenocarcinoma Concomitant with Intraductal Papillary Mucinous Neoplasm

66. ASO Visual Abstract: Comprehensive Analysis of Molecular Biological Characteristics of Pancreatic Ductal Adenocarcinoma Concomitant with Intraductal Papillary Mucinous Neoplasm

67. Inhibition of Clusterin Represses Proliferation by Inducing Cellular Senescence in Pancreatic Cancer

68. ASO Author Reflections: A Novel Mechanism of Suppressing Proliferation After Inhibition of Clusterin in Pancreatic Cancer

69. ASO Visual Abstract: Inhibition of Clusterin Represses Proliferation by Inducing Cellular Senescence in Pancreatic Cancer

70. Evaluation of HLA-E Expression Combined with Natural Killer Cell Status as a Prognostic Factor for Advanced Gastric Cancer

71. ASO Visual Abstract: Evaluation of HLA-E Expression Combined with Natural-Killer Cell Status as a Prognostic Factor for Advanced Gastric Cancer

72. Recurrence After Resection of Pancreatic Cancer: Can Radiomics Predict Patients at Greatest Risk of Liver Metastasis?

73. ASO Author Reflections: Predicting Pancreatic Cancer Liver Metastasis by Integrating Primary Tumor Clinicopathologic Features and Liver Radiomics

74. ASO Visual Abstract: Recurrence After Resection of Pancreatic Cancer – Can Radiomics Predict Patients at Greatest Risk of Liver Metastasis?

75. Resectability Status of Pancreatic Cancer Having Tumor Contact with an Aberrant Right Hepatic Artery: Is Upfront Surgery Justified?

76. ASO Author Reflections: Pancreatic Cancer Having Tumor Contact with an Aberrant Right Hepatic Artery Should be Regarded as Technically Resectable but Oncologically Borderline-Resectable

77. ASO Visual Abstract: Resectability Status of Pancreatic Cancer Having Tumor Contact with an Aberrant Right Hepatic Artery: Is Upfront Surgery Justified?

78. The Association Between Neoadjuvant Therapy and Pathological Outcomes in Pancreatic Cancer Patients After Resection: Prognostic Significance of Microscopic Venous Invasion

79. ASO Author Reflections: Neoadjuvant Therapy for Pancreatic Cancer may Reduce Microscopic Venous Invasion, Which is an Independent Prognostic Factor Associated with Liver Recurrence

80. ASO Visual Abstract: The Association Between Neoadjuvant Therapy and Pathological Outcomes in Pancreatic Cancer Patients After Resection: Prognostic Significance of Microscopic Venous Invasion

81. Predictors of Long-Term Survival in Pancreatic Ductal Adenocarcinoma after Pancreatectomy: TP53 and SMAD4 Mutation Scoring in Combination with CA19-9

82. ASO Author Reflections: Constructed Scoring System Using TP53 and SMAD4 Mutations Combined with Carbohydrate Antigen 19-9 in Pancreatic Ductal Adenocarcinoma

83. Radiographical Evaluation of Tumor Immunosuppressive Microenvironment and Treatment Outcomes in Gastric Cancer: A Retrospective, Multicohort Study

84. ASO Author Reflections: Radiomic Immunosuppressive Scoring System for Predicting Prognosis and Chemotherapy Benefit in Gastric Cancer

85. ASO Visual Abstract: Radiographical Evaluation of Tumor Immunosuppressive Microenvironment and Treatment Outcomes in Gastric Cancer: A Retrospective, Multicohort Study

86. Optimizing Indications for Conversion Surgery Based on Analysis of 454 Consecutive Japanese Cases with Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel: A Single-Center Retrospective Study

87. ASO Author Reflections: What are the Indications for Conversion Surgery for Initially Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel? Is Surgery Really Worthwhile after Sufficient Chemotherapy?

88. ASO Visual Abstract: Optimizing the Indications for Conversion Surgery Based on an Analysis of 454 Consecutive Japanese Cases with Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel: A Single-Center Retrospective Study

89. Correction to: More is More? Total Pancreatectomy for Periampullary Cancer as an Alternative in Patients with High-Risk Pancreatic Anastomosis: A Propensity Score-Matched Analysis

90. It’s Not About the Money: Continued Treatment and Survival Outcome Disparities in Minority Rectal Cancer Patients After Controlling for Socioeconomic Factors

91. ASO Author Reflections: Inequities in Rectal Cancer Treatment and Survival

92. ASO Visual Abstract: It’s Not About the Money: Continued Treatment and Survival Outcome Disparities in Minority Rectal Cancer Patients After Controlling for Socioeconomic Factors

93. Laparoscopic Complete Mesocolic Excision with Central Vascular Ligation (CME + CVL) for Right-Sided Colon Cancer: A New “Superior Mesenteric Artery First” Approach

94. ASO Author Reflections: A New “Superior Mesenteric Artery-First” Approach for Complete Mesocolic Excision with Central Vascular Ligation in Laparoscopic Right Hemicolectomy

95. Comparison of Standard D2 and Limited Lymph Node Dissection in Elderly Patients with Advanced Gastric Cancer

96. ASO Visual Abstract: Comparison of Standard D2 and Limited Lymph Node Dissection in Elderly Patients with Advanced Gastric Cancer

97. Safety and Efficacy of Intraperitoneal Paclitaxel Plus Intravenous Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX) for Gastric Cancer with Peritoneal Metastasis

98. ASO Visual Abstract: Safety and Efficacy of Intraperitoneal Paclitaxel Plus Intravenous Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX) for Gastric Cancer with Peritoneal Metastasis

99. A National Assessment of T2 Staging for Intrahepatic Cholangiocarcinoma and the Poor Prognosis Associated with Multifocality

100. ASO Author Reflections: Disparate Outcomes in Stage II Intrahepatic Cholangiocarcinoma: A Case for Upstaging Multifocal Tumors

101. ASO Visual Abstract: A National Assessment of T2 Staging for Intrahepatic Cholangiocarcinoma and the Poor Prognosis Associated with Multifocality

102. Letter to Editor of Annals of Surgical Oncology Concerning “Early Diagnosis of Anastomotic Leakage after Gastric Cancer Surgery via Analysis of Inflammatory Factors in Abdominal Drainage”

103. Impact of Body Mass Index on Surgical Outcomes in Oncologic Microvascular Head and Neck Reconstruction

104. ASO Visual Abstract: Impact of Body Mass Index on Surgical Outcomes in Oncologic Microvascular Head and Neck Reconstruction

105. Benchmarking Survival Outcomes Following Surgical Management of pT3 and pT4 Cutaneous Squamous Cell Carcinoma of the Head and Neck

106. ASO Author Reflections: Surgery for pT3 and pT4 Cutaneous Squamous Cell Carcinomas of the Head and Neck Provides Robust Outcomes Against Which Emerging Treatment Modalities Should be Compared to Determine Their Role in the Standard of Care

107. ASO Visual Abstract: Benchmarking Survival Outcomes Following Surgical Management of pT3 and pT4 Cutaneous Squamous Cell Carcinoma of the Head and Neck

108. Correction to: Guide to Enhanced Recovery for Cancer Patients Undergoing Surgery: Head and Neck Cancer

109. Role of Preoperational Imaging Traits for Guiding Treatment in Single ≤ 5 cm Hepatocellular Carcinoma

110. ASO Author Reflections: Intertumor Biological Heterogeneity Counts in Treatment Selection of Single ≤ 5 cm Hepatocellular Carcinoma

111. Outcomes of Mixed Pathologic Response in Patients with Multiple Colorectal Liver Metastases Treated with Neoadjuvant Chemotherapy and Liver Resection

112. ASO Visual Abstract: Outcomes of Mixed Pathologic Response in Patients with Multiple Colorectal Liver Metastases Treated with Neoadjuvant Chemotherapy and Liver Resection

113. Gallbladder Cancer: A Single-Institution 10-Year Experience—Analysis of Adenocarcinoma Subtypes and Tumors Arising from Intracholecystic Papillary Neoplasms

114. ASO Visual Abstract: Gallbladder Cancer: A Single-Institution 10-Year Experience—Analysis of Adenocarcinoma Subtypes and Tumors Arising From Intracholecystic Papillary Neoplasms

115. Association of County-Level Upward Economic Mobility with Stage at Diagnosis and Receipt of Curative-Intent Treatment among Patients with Hepatocellular Carcinoma

116. ASO Author Reflections: Association of County-level Upward Economic Mobility with Stage at Diagnosis and Receipt of Curative-Intent Treatment Among Patients with Hepatocellular Carcinoma

117. ASO Visual Abstract: Association of County-Level Upward Economic Mobility with Stage at Diagnosis and Receipt of Curative-Intent Treatment Among Patients with Hepatocellular Carcinoma

118. Hepatic Resection Combined with Intraoperative Radiofrequency Ablation Versus Hepatic Resection Alone for Selected Patients with Moderately Advanced Multifocal Hepatocellular Carcinomas

119. ASO Author Reflections: How to Choose the Optimal Strategy to Treat Patients with Moderately Advanced Multifocal Hepatocellular Carcinomas?

120. ASO Visual Abstract: Hepatic Resection Combined With Intraoperative Radiofrequency Ablation Versus Hepatic Resection Alone for Selected Patients With Moderately Advanced Multifocal Hepatocellular Carcinomas

121. Correction to: Clinical Features of Recurrence After Hepatic Resection for Early-Stage Hepatocellular Carcinoma and Long-Term Survival Outcomes of Patients with Recurrence: A Multi-institutional Analysis

122. Prognostic Significance of Primary Tumor-Infiltrating Lymphocytes in a Contemporary Melanoma Cohort

123. ASO Author Reflections: Prognostic Significance of Primary Tumor Infiltrating Lymphocytes in the Contemporary Melanoma Era

124. ASO Visual Abstract: Prognostic Significance of Primary-Tumor-Infiltrating Lymphocytes in a Contemporary Melanoma Cohort

125. An Evidence-Based Staging System for Mucosal Melanoma: A Proposal

126. ASO Author Reflections: Staging System for Mucosal Melanoma: A Proposal to Fill a Gap

127. ASO Visual Abstract: An Evidence-Based Staging System for Mucosal Melanoma: a Proposal

128. Comments on Post-Publication Discussion of “Evaluation of a Gene Expression Profiling Assay in Primary Cutaneous Melanoma”

129. Correction to: Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)

130. Feasibility and Safety of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy With or Without Intraoperative Intravenous 5-Fluorouracil and Leucovorin for Colorectal Peritoneal Metastases: A Multicenter Comparative Cohort Study

131. ASO Author Reflections: Is There Still a Role for Intraperitoneal Oxaliplatin for Colorectal Peritoneal Metastases?

132. ASO Visual Abstract: Feasibility and Safety of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy with or Without Intraoperative Intravenous 5-Fluorouracil and Leucovorin for Colorectal Peritoneal Metastases: A Multicenter Comparative Cohort Study

133. In Patients Undergoing CRS/HIPEC for Colorectal Adenocarcinoma with Peritoneal Metastases, Presence of Ascites on Computed Tomography Imaging is not a Prognostic Marker for Survival

134. ASO Visual Abstract: In Patients Undergoing CRS/HIPEC for Colorectal Adenocarcinoma with Peritoneal Metastases, Presence of Ascites on Computed Tomography Imaging is Not a Prognostic Marker for Survival

135. Correction: Microsatellite and RAS/RAF Mutational Status as Prognostic Factors in Colorectal Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

136. Matched Preliminary Analysis of Patient-Reported Outcomes following Autologous and Implant-Based Breast Reconstruction

137. ASO Author Reflections: Deeper Understanding of Patient-Reported Outcomes in Breast Reconstruction Patients Not Requiring Radiation Therapy: Harnessing Propensity Matching Methodology

138. A Matched Preliminary Analysis of Patient-Reported Outcomes After Autologous and Implant-Based Breast Reconstruction

139. BREAST-Q REACT: Clinical Reference Values for the BREAST-Q in Post-mastectomy Breast Reconstruction Patients

140. ASO Author Reflections: Patient-Reported Outcomes for Breast Reconstruction Clinical Practice

141. ASO Visual Abstract: BREAST-Q REACT—Clinical Reference Values for the BREAST-Q in Post-mastectomy Breast Reconstruction Patients

142. Construction and Verification of Risk Predicting Models to Evaluate the Possibility of Venous Thromboembolism After Robot-Assisted Radical Prostatectomy

143. Prognostic Role of Preoperative Vascular Cell Adhesion Molecule-1 Plasma Levels in Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy

144. ASO Author Reflections: Is Vascular Cell Adhesion Molecule-1 (VCAM-1) a Promising Biomarker in Urothelial Carcinoma of the Bladder?

145. ASO Visual Abstract: Prognostic Role of Preoperative Vascular Cell Adhesion Molecule-1 Plasma Levels in Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy

146. Effect of Papaverine on Renal Artery Blood Flow during Robot-Assisted Partial Nephrectomy: A Randomized Controlled Study

147. ASO Author Reflections: Papaverine and Beneficial Renal Effects in Robot-Assisted Partial Nephrectomy

148. ASO Visual Abstract: Effect of Papaverine on Renal Artery Blood Flow During Robot-Assisted Partial Nephrectomy

149. Utility of Postoperative Serial Renal Function Monitoring in Patients Undergoing Radical Cystectomy for Urothelial Carcinoma

150. ASO Visual Abstract: Examining the Utility of Postoperative Serial Renal Function Monitoring in Patients Undergoing Radical Cystectomy for Urothelial Carcinoma